The ocular allergic response: A pharmacotherapeutic review

Formulary

Volumn 39, Issue 4, 2004, Pages 213-222

  Slonim, Charles B ^a,b   Boone, Roderick ^c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b SANTEN PHARMACEUTICAL CO LTD   (Japan)

^c CareGroup Health System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFREX; ANTIALLERGIC AGENT; ARTIFICIAL TEAR; AZELASTINE; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; EMEDASTINE; EPINASTINE; KETOROLAC; KETOROLAC TROMETAMOL; KETOTIFEN FUMARATE; LEVOCABASTINE; LODOXAMIDE TROMETAMOL; NEDOCROMIL SODIUM; OLOPATADINE; PEMIROLAST; STEROID; VASOCONSTRICTOR AGENT;

ALLERGIC CONJUNCTIVITIS; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DRUG ACTIVITY; DRUG COST; DRUG DOSE REGIMEN; DRUG MECHANISM; EOSINOPHIL; EPIDEMIOLOGICAL DATA; ERYTHEMA; GENERAL PRACTITIONER; HUMAN; INFLAMMATION; MEDICAL DECISION MAKING; PATHOPHYSIOLOGY; PHYSICIAN; PRIMARY MEDICAL CARE; PRURITUS; REVIEW; TREATMENT INDICATION;

EID: 2042421519     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. American Academy of Allergy, Asthma and Immunology (AAAAI). The Allergy Report: Science Based Findings on the Diagnosis & Treatment of Allergic Disorders, 1996-2001. Milwaukee, Wis: American Academy of Allergy, Asthma and Immunology; 2001.
2. Epstein AB. The impact of ocular allergy. Rev Optometry. 2001;138:4.
3. al-Laith M, Pearce FL. On the mechanism of action of sodium orthovanadate in inducing histamine release from rat peritoneal mast cells. Int Arch Allergy Immunol. 1993;101:385-391.
4. Abelson MB, Udell IJ, Weston JH. Conjunctival eosinophils in compound 48/80 rabbit model. Arch Ophthalmol. 1983;101:631-633.
5. Trocme SD, Kephart GM, Allansmith MR, et al. Conjunctival deposition of eosinophil granule major basic protein in vernal keratoconjunctivitis and contact lens-associated giant papillary conjunctivitis. Am J Ophthalmol. 1989;108:57-63.
6. Gleich GJ, Frigas E, Loegering DA, et al. Cyto toxic properties of the eosinophil major basic protein. J Immunol. 1979;123:2925-2927.
7. Trocme SD, Gleich GJ, Zieske JD. Eosinophil granule major basic protein inhibits corneal epithelial wound healing in vitro [abstract]. Invest Ophthalmol Vis Sci. 1991;32(suppl):1161.
8. Trocme SD, Kephart GM, Bourne WM, et al. Eosinophil granule major basic protein in corneal ulcers associated with vernal keratoconjunctivitis. Am J Ophthalmol. 1993;115:640-643.
9. Abelson MB, Allansmith MR. In: Silverstein AM, O'Connor ER, eds. Immunology and Immunopathology of the Eye. NewYork: Masson; 1979:362-364.
10. 2 receptors in the human ocular surface. Arch Ophthalmol. 1981;99:302-304.
11. Ash ASF, Schild HO. Receptors mediating some actions of histamine. Br J Pharmacol Chemother. 1966;27:427-439.
12. Rubin RM, Samples JR, Rosenbaum JT. Prostaglandin-independent inhibition of ocular vascular permeability by a platelet-activating factor antagonist. Arch Ophthalmol. 1988;106:1116-1120.
13. Smith MJH. Biological activities of leukotriene B4 (isomer III). Adv Prostaglandin Thromboxane Leukotriene Res. 1982;9:283-292.
14. Woodward DF, Ledgard SE. Comparison of leukotrienes as conjunctival microvascular permeability factors. Ophthalmic Res. 1985;17:318-320.
15. Spada CS, Woodward DF, Hawley SB, et al. Leukotrienes cause eosinophil emigration into conjunctival tissue. Prostaglandins. 1986;31:795-809.
16. Trocme SD, Gilbert CM, Allansmith MR, et al. Characteristics of the cellular response of the rat conjunctiva to topically applied leukotriene B4. Ophthalmic Res. 1989;21:297-302.
17. Hedqvist P, Dahlen Dahlén SE, Gustafsson L, et al. Biological profile of leukotrienes C4 and D4. Acta Physiol Scand. 1980;110:331-333.
18. Drazen JM, Austen KF, Lewis RA, et al. Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci USA. 1980;77:4354-4358.
19. Rothenberg ME, Owen WF, Stevens RL. Ocular Allergy. Mast cells and eosinophils. Int Ophthalmol Clin. 1988;28:267-274.
20. Goetzl E J, Gorman RR. Chemotactic and chemokinetic stimulation of human eosinophil and neutrophil polymorphonuclear leukocytes by 12-L-hydroxy-5,8,10-hepta-decatrienoic acid (HHT). J Immunol. 1978;120:526-531.
21. Lewis RA, Sorer NA, Diamond PT, et al. Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol. 1982;129:1627-1631.
22. Abelson MB, Madiwale NA, Weston JH. The role of prostaglandin D2 in allergic ocular disease. In: O'Connor GR, Chandler JW, eds. Third International Symposium on the Immunology and Immunopathology of the Eye. New York: Masson & Co; 1985:163-166.
23. Solomon LM, Juhlin L, Kirschenbaum MB. Prostaglandin on cutaneous vasculature. J Invest Dermatol. 1968;51:280-282.
24. Crounkhorn P, Willis AL. Interaction between prostaglandins E and F given intradermally in the rat. Br J Pharmacol. 1971;41:507-512.
25. Abelson M, Smith L. Mediators of Ocular Inflammation. In: Tasman W, Jaeger EA, eds. Duane's Ophthalmology. Philadelphia: Lippincott Williams & Wilkins; 1999.
26. 2. Science. 1976;193:1135.
27. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA. 1975;72:2994-2998.
28. Killon KH, Kastrup EK, eds. Drug Facts and Com parisons. St. Louis, Mo: Facts and Comparisons, Wolters Kluwer Health, Inc.; 2004:1746-1765.
29. Price Alert Feb 15, 2004 issue by Medi-Span. Indianapolis, Ind: Wolters Kluwer Health, Inc; 2004.
30. Butrus S, Greiner JV, Discepola M, Finegold I. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. Clin Ther. 2000;22:1462-1472.
31. Abelson MB, George MA, Smith LM. Evaluation of 0.05% levocabastine versus 4% sodium cromolyn in the allergen challenge model. Ophthalmology. 1995;102:310-316.
32. Foster CS, and the Cromolyn Sodium Collaborative Study Group. Evaluation of topical cromolyn sodium in the treatment of vernal keratoconjunctivitis. Ophthalmol. 1988;95:194-201.
33. Bielory L. Role of antihistamines in ocular allergy. Am J Med. 2002;113(suppl 9A):34S-37S.
34. Verin P, Easty DL, Secchi A, et al. Clinical evaluation of twice-daily emedastine 0.05% eye drops versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis. Am J Ophthalmol. 2001;131:691-698.
35. Netland PA, Leahy C, Krenzer KL. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model. Am J Ophthalmol. 2000;130:717-723.
36. Optivar [package insert]. Someret, NJ: MedPointe Pharmaceuticals; 2003.
37. Zaditor [package insert]. Duluth, Ga: CIBA Vision, a Novartis Company; 1999.
38. Chand N, Sofia RD. Azelastine-a novel in vivo inhibitor of leukotriene biosynthesis: a possible mechanism of action: a mini review. J Asthma. 1995:32:227-234.
39. Cook EB, Stahl JL, Barney NP, Graziano FM. Olopatadine inhibits anti-immunoglobin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells. Ann Allergy Asthma Immunol. 2001;87:424-429.
40. Spangler DL, Bensch G, Berdy GJ. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin Ther. 2001;23:1272-1280.
41. Aguilar AJ. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Acta Ophthalmol Scand. 2000;230(suppl):52-55.
42. Deschenes J, et al. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. Acta Ophthalmol Scand. 1999; 228(suppl):47-52.
43. Hirasawa N, Funaba Y, Hirano Y, et al. Inhibition by dexamethasone of histamine production in allergic inflammation in rats. J Immunol. 1990;145:3041-3046.
44. Charap AD. Corticosteroids. In: Tasman W, Jaeger EA, eds. Duane's Ophthalmology. Philadelphia: Lippincott Williams & Wilkins; 1992:9.
45. Van der Velden VH. Glucocorticoids: mechanisms of action and anti-inflammatory potential in asthma. Mediators Inflamm. 1998;7:229-237.
46. Ilyas H, et al. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens. 2004;30:10-13.
47. Abelson MB, Smith L, Chapin M. Ocular allergic disease: Mechanisms, disease sub-types, treatment. Ocular Surface. 2003;1:144.